-
Uncategorized1 week ago
Kailera plans IPO for Phase 3 obesity drug from Hengrui
Kailera plans IPO for Phase 3 obesity drug from Hengrui
-
Uncategorized1 week agoSTAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Alex Zhavoronkov, CEO of Insilico Medicine, can’t stop complimenting Eli Lilly. “Lilly is better in AI than Insilico, and no other company is better in AI...
-
Uncategorized1 week ago
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
-
Uncategorized1 week ago
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
-
Uncategorized1 week ago
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone after...
-
Endpoints News1 week ago
A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and more
Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below for...
-
GEN – Genetic Engineering & Biotechnology News2 weeks ago
Bioengineered Implants Deliver Multi-Drug Therapy in Animal Models
In a new paper, scientists from Northwestern University and their collaborators at Rice University and Carnegie Mellon University report on their progress towards developing so-called implantable...
-
GEN – Genetic Engineering & Biotechnology News2 weeks agoGut-Immune Link Identified in Multiple Sclerosis-Related Neuroinflammation
Multiple sclerosis (MS) is a debilitating neurological disorder caused by malfunctioning immune responses that target the brain and spinal cord of the central nervous system (CNS)....
-
STAT News – Biotech2 weeks agoSTAT+: Amid focus on food, FDA leader briefs lawmakers on priorities
WASHINGTON — Food and Drug Administration officials briefed senators on the agency’s plans for food policy for 2026, according to a person familiar with the meeting....
-
Endpoints News2 weeks ago
Otsuka buys Transcend Therapeutics for $700M upfront
Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide the...
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
